Adapt Investment Managers’s Amgen AMGN Stock Holding History

Adapt Investment Managers’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250,000	Closed	-$81.8M	–	138
2025 Q4	$81.8M	Buy	250,000 +150,000	+150%	+$47.6M	0.6%	27
2025 Q3	$28.2M	Buy	+100,000	New	+$29M	0.27%	60
2025 Q1	–	Sell	-200,000	Closed	-$52.5M	–	66
2024 Q4	$52.5M	Buy	+200,000	New	+$59.3M	1.36%	13

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Adapt Investment Managers's AMGN Position: Q1 2025 in Review

Adapt Investment Managers sold out of Amgen (AMGN) in Q1 2025, closing a stake of 40,279 shares — an estimated $10.6M sold.

Adapt Investment Managers first reported a position in AMGN in Q4 2024 and held it in 1 quarter. The position peaked at $10.6M in Q4 2024. 2,927 funds tracked by Wall St. Rank hold AMGN as of Q1 2025.

Adapt Investment Managers reported no remaining Amgen position as of Q1 2025 after selling out during the quarter.
Adapt Investment Managers sold 40,279 Amgen shares in Q1 2025, an estimated $10.6M.
Adapt Investment Managers first reported a position in Amgen in Q4 2024 and held it in 1 quarter.
Adapt Investment Managers's Amgen position peaked at $10.6M in Q4 2024.
2,927 funds tracked by Wall St. Rank held Amgen as of Q1 2025.

Based on Adapt Investment Managers's 13F filing for Q1 2025, filed 14 May 2025.